Keogh KA, Dolin P, Kielar D, Shavit A, Rowell J, Edmonds C, Meyers J, Esterberg E, Nham T, Chen SY. Pulmonary and cardiovascular involvement and persistent damage in eosinophilic granulomatosis with polyangiitis: a retrospective analysis of US health insurance claims data. Poster presented at the CHEST 2024; October 9, 2024. Boston, MA. [abstract] Chest. 2024 Oct; 166(4, Suppl):A5373-A57.
Rebordosa C, Plana E, Rubino A, Aguado J, Martinez D, Lei A, Daoud S, Saigi-Morgui N, Perez-Gutthann S, Rivero-Ferrer E. Risk assessment of acute myocardial infarction and stroke associated with long-acting muscarinic antagonists, alone or in combination, versus long-acting beta2-agonists. Int J Chron Obstruct Pulmon Dis. 2022 Aug 2;17:1715-33. doi: 10.2147/COPD.S363997
Rebordosa C, Plana E, Rubino A, Aguado J, Lei A, Daoud S, Saigi-Morgui N, Perez-Gutthann S, Rivero-Ferrer E. A cohort study to evaluate the risk of hospitalisation for congestive heart failure associated with the use of aclidinium and other chronic obstructive pulmonary disease medications in the UK Clinical Practice Research Datalink. Int J Chron Obstruct Pulmon Dis. 2021 May 31;16:1461-75. doi: 10.2147/COPD.S301624
Ayad M, Karanth S, Patel B. A quality improvement initiative to determine the outcomes of creating an automated repeat lactate order in sepsis patients with lactate levels greater than or equal 2 mmol/l. Poster presented at the CHEST 2018 Annual Meeting; October 2018. [abstract] Chest. 2018 Oct; 154(4):321A. doi: 10.1016/j.chest.2018.08.294
Simou E, Leonardi-Bee J, Britton J. The effect of alcohol consumption on the risk of ARDS: a systematic review and meta-analysis. Chest. 2018 Jul;154(1):58-68. doi: 10.1016/j.chest.2017.11.041
Donohue IF, Bollu VK, Stull DE, Nelson LM, Williams VS, Stensland MD, Hanania NA. Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial. Int J Chron Obstruct Pulmon Dis. 2018 Feb 5;13:499-508.
Sanchez-de-la-Torre A, Soler X, Barbe F, Flores M, Maisel A, Malhotra A, Rue M, Bertran S, Aldoma A, Worner F, Valls J, Lee CH, Turino C, Galera E, De Batlle J, Sanchez-de-la-Torre M, Spanish Sleep Network. Cardiac troponin levels in patients with acute coronary syndrome and sleep apnea: a pilot study. Chest. 2018 Feb;153(2):329-38. doi: 10.1016/j.chest.2017.06.046
Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model. Int J Chron Obstruct Pulmon Dis. 2017 Mar 24;2017(12):997-1008.
Donohue J, Ganapathy V, Davenport E, Nelson L, Zhao X. COPD-related hospitalizations associated with arformoterol tartrate treatment among patients receiving concomitant tiotropium (TIO) therapy: post hoc analyses from a 52-week randomized, controlled study. Poster presented at the CHEST 2016 Annual Meeting; October 24, 2016. Los Angeles, CA. [abstract] Chest. 2016 Oct; 150(4_S). doi: 10.1016/j.chest.2016.08.990
Rycroft CE, Heyes A, Lanza L, Becker K. Epidemiology of chronic obstructive pulmonary disease: a literature review. Int J Chron Obstruct Pulmon Dis. 2012 Jul 1;7:457-94.
Herring WL, Herrmann JW. The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics. OR spectrum: quantitative approaches in management. 2012 Apr 1;34(2):429-59.
Dalal AA, Demuro-Mercon C, Lewis S, Nelson L, Gilligan T, McLeod L. Validation of alternate modes of administration of the lung function questionnaire (LFQ) in subjects with smoking history. Int J Chron Obstruct Pulmon Dis. 2010 Dec 1;5:425-34.
Rodriguez E, Ferrer J, Marti S, Zock JP, Plana E, Morell F. Impact of occupational exposure on severity of COPD. Chest. 2008 Dec;134(6):1237-43.
Massanari M, Sacco P, Kianifard F, Maykut R, Zeldin R. Addition of omalizumab improved measures of impairment associated with moderate-severe persistent asthma. Poster presented at the American College of Chest Physicians; October 2008. Philadelphia, PA. [abstract] Chest. 134(4_MeetingAbstracts):95001.
Delea T, Hagiwara M, Borker R, Stanford R. Observational study of the risk of ED visit or hospitalization in COPD patients receiving maintenance therapies: a time-dependent analysis. Presented at the 71st Annual Chest International Meeting; October 2005. Montreal, Canada. [abstract] Chest. 2005 Oct; 128(4 Supplement):178S. doi: 10.1378/chest.128.4_MeetingAbstracts.178S-a
Borker RD, Watkins M, Knobil K, Emmett A, Kalberg C. Using distribution-based standard error of measurement (SEM) method to determine minimal important difference (MID) for the symptom status index (SSI). Poster presented at the CHEST 2005: 71st Annual Meeting of the American College of Chest Physicians; October 29, 2005. Montreal, Canada. [abstract] Chest. 2005 Oct; 128(4 supplement):251S.
Borker RD, Hayflinger C, Stanford R. Risk of hospitalization/emergency visit in patients with chronic obstructive pulmonary disease by initial medication regimen. Poster presented at the CHEST 2005: 71st Annual Meeting of the American College of Chest Physician; October 2005. [abstract] Chest. 2005 Oct; 128(4 Supplement):257S.
Riedel A, Chastek B, Borker RD. Healthcare and economic burden in undiagnosed chronic obstructive pulmonary disease (COPD) patients. Presented at the 71st Annual Chest International Meeting; October 2005. Montreal, Canada. [abstract] Chest. 2005 Oct; 128(4 Supplement):123S.
Fischer TL, Borker R, Barnhart F, Morris A, Zhu J. Effect of cilomilast on chronic obstructive pulmonary disease (COPD) patients with impaired quality of life (QOL). Presented at the 69th Annual Chest International Meeting; January 2003. Orlando, FL. [abstract] Chest. 2003 Jan; 124(4 Supplement):129S. doi: 10.1378/chest.124.4_MeetingAbstracts.129S